Clinical trial · Interventional
Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy
Cardioprotection of Silymarin for Patients Received Anthracycline Chemotherapy
NCT04434404CI-TRIAL-00045547completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
the study aim to protect patients received anthracyclines containing chemotherapy from cardiotoxcity induced by anthracyclines derivatives. by using L-carnitine and Silymarin for protection the heart from anthracyclines toxicities, and in addition its a comparitive study between L-carnitine and Silymarin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| L-Carnitine 500Mg Oral Tablet | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- PLACEBO_COMPARATOR
- label
- control group
- description
- 33, patients in the control group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 without cardioprotective agents
- interventionNames
- Drug: L-Carnitine 500Mg Oral Tablet
- type
- ACTIVE_COMPARATOR
- label
- L-carnitine group
- description
- 25 patients received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine
- interventionNames
- Drug: L-Carnitine 500Mg Oral Tablet
- type
- ACTIVE_COMPARATOR
- label
- Silymarin group
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * cancer patients receiving anthracycline chemotherapy in their protocol alone (without any cardioprotective agent), * aged 20-60 and * female patients were included. Exclusion Criteria: * patients with a history of heart failure, arrhythmia, history of cardiac catheterizations or, history of angina, uncontrolled hypertension and uncontrolled diabetes, * patients with impaired liver function tests, * previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens, * previous history of chest wall irradiation. * Brain metastasis, * pregnant patients and * patients who refused informed consent,
References
Publications (0)
Data not yet available
No reference posted for this study.